67 research outputs found
Investigation of Alternative Deicers for Snow and Ice Control
This technical report presents the findings of the laboratory analysis of potassium succinate (KSu) as a roadway deicer. Laboratory analysis included modified SHRP ice-melting testing, a differential scanning calorimetry (DSC) thermogram, and friction measurements to quantify performance. The overall results indicate that the performance of KSu is similar to that of NaCl at improving friction on roadways during snow and ice conditions. The results of DSC suggest that KSu can be applied as a roadway deicer at -5°C (23°F) and above. However, KSu does not function as a deicer at colder temperatures where salt brine will work (the generally agreed upon lowest working temperature for salt brine is 15°F [-9.5°C]). The results of the laboratory testing show that KSu functions as a roadway deicer with slightly lower ice-melting rates than salt brine. The ice-melting rates, DSC, and friction performance testing of KSu show that the product performs as a deicer at warmer temperatures than salt brine, with slightly less ice-melting capacity and similar friction performance. Based on these and previous results showing lack of corrosion in metals, equipment, and pavements from use of KSu and similar BOD of KSu to potassium acetates, KSu appears to be a viable option as a roadway deicer at temperatures at or above -5°C (23°F). Use of KSu as a roadway deicer may be focused in areas where there are concerns about impacts to infrastructure, equipment, or pavements, such as on bridges, elevated roadways, in parking garages, or on newer concrete pavements. Potential concerns with the use of KSu as a roadway deicer are its price, lack of full-scale manufacturing of KSu at this time, and the BOD exerted by the product. Additional testing to fully quantify the environmental impacts of KSu on soil, water, flora, and fauna is recommended. If water quality and BOD are of concern, application of this product is not recommended in large quantities and during times of low water flow
Estimating the Application Rate of Liquid Chloride Products Based on Residual Salt Concentration on Pavement
This technical report summarizes the results of laboratory testing on asphalt and concrete pavement. A known quantity of salt brine was applied as an anti-icer, followed by snow application, traffic simulation, and mechanical snow removal via simulated plowing. Using a sample from this plowed snow, researchers measured the chloride concentration to determine the amount of salt brine (as chloride) that remained on the pavement surface. Under the investigated scenarios, the asphalt samples showed higher concentrations of chloride in the plowed-off snow, and therefore lower concentrations of chlorides remaining on the pavement surface. In comparison, the concrete samples had much lower chloride concentrations in the plowed-off snow, and much higher chloride concentrations remaining on the pavement surface. An interesting pattern revealed by the testing was the variation in the percentage of residual chloride on the pavement surface with changes in temperature. When pavement type was not considered, more residual chloride was present at warmer temperatures and less residual chloride was present at colder temperatures. This observation warrants additional testing to determine if the pattern is in fact a statistically valid trend. The findings from the study will help winter maintenance agencies reduce salt usage while meeting the defined Level of Service. In addition, findings will contribute to environmentally sustainable policies and reduce the level of salt usage (from snow- and ice-control products) introduced into the environment
Pavement Surface Treatments for Ice-Prone Locations in the Illinois Highway System
This project aims to identify and evaluate effective and durable pavement surface treatments (PSTs) suitable for implementation
at Illinois Department of Transportation (IDOT) ice-prone locations. A user-friendly questionnaire of northern states and
international transportation agencies was developed to capture practitioner insights and collect more detailed information about
the current practices of using PSTs for ice prevention. A comprehensive review of existing research and agency practices both
nationally and internationally in using PSTs for icy/slippery pavement condition prevention was conducted. The review focused
on built-in technologies such as the use of highly rough surface texture, slow-release freezing point depressant, or
superhydrophobic additive in asphalt pavement, to identify candidate technologies for the project. PSTs have not been widely
adopted by state or local agencies, even for select ice-prone locations. None of the PSTs identified and reviewed have
demonstrated long-term success or significant enough potential for the Illinois Center for Transportation (ICT) Technical Review
Panel to be comfortable with; as such, the project was wrapped up without further laboratory tests and life-cycle analyses. Some
of these built-in PST technologies are promising but all of them, other than high friction surface treatment (HFST), are premature
at this stage for any field deployment by Illinois. The major concerns stem from their high cost of implementation and potential
lack of long-term durability as an effective anti-icing tool. IDOT should consider conducting traffic safety analyses of their high
friction surface treatment (HFST) sites, including winter maintenance operations data and winter crash statistics.IDOT-R27-187Ope
The Grizzly, December 1, 1989
Curriculum in Transition • Armstrong\u27s Talk a Trauma • Letters: Maturity Decides Right Choice; Everybody\u27s a Critic; Championship Cycling; PDA Pooh-Poohed; Pro-Choice Rally Ironic • Aquatic Lady Bears Stroke Strongly • Hoopsters Hopeful • Women\u27s Track Looks to Season • Congrats to Athletes • Shoudt to Return Next Fall • X-Country Wrap-Up • Swimmers Victorious • Down with Frats • Faith-Leaps Abound • EPA: Not a Joking Matter • What Can Clamer Claim? • Victims of Fishy Business • Corsonites Fashion Comatose • Greeks Promote Sexism • U.C. Honors Spotlight • Final Exam Schedulehttps://digitalcommons.ursinus.edu/grizzlynews/1248/thumbnail.jp
Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis
BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8; 21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, similar to 40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21)
High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting
The ability to track microbes in real time in vivo is of enormous value for preclinical investigations in infectious disease or gene therapy research. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumours following systemic administration. Bioluminescent Imaging (BLI) represents a powerful tool for use with bacteria engineered to express reporter genes such as lux. BLI is traditionally used as a 2D modality resulting in images that are limited in their ability to anatomically locate cell populations. Use of 3D diffuse optical tomography can localize the signals but still need to be combined with an anatomical imaging modality like micro-Computed Tomography (μCT) for interpretation
Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study
BACKGROUND: Little is known about current clinical practice concerning peri-operative red blood cell transfusion in neonates and small infants. Guidelines suggest transfusions based on haemoglobin thresholds ranging from 8.5 to 12 g dl-1, distinguishing between children from birth to day 7 (week 1), from day 8 to day 14 (week 2) or from day 15 (≥week 3) onwards. OBJECTIVE: To observe peri-operative red blood cell transfusion practice according to guidelines in relation to patient outcome. DESIGN: A multicentre observational study. SETTING: The NEonate-Children sTudy of Anaesthesia pRactice IN Europe (NECTARINE) trial recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. PATIENTS: The data included 5609 patients undergoing 6542 procedures. Inclusion criteria was a peri-operative red blood cell transfusion. MAIN OUTCOME MEASURES: The primary endpoint was the haemoglobin level triggering a transfusion for neonates in week 1, week 2 and week 3. Secondary endpoints were transfusion volumes, 'delta haemoglobin' (preprocedure - transfusion-triggering) and 30-day and 90-day morbidity and mortality. RESULTS: Peri-operative red blood cell transfusions were recorded during 447 procedures (6.9%). The median haemoglobin levels triggering a transfusion were 9.6 [IQR 8.7 to 10.9] g dl-1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl-1 in week 2 and 8.0 [7.3 to 9.0] g dl-1 in week 3. The median transfusion volume was 17.1 [11.1 to 26.4] ml kg-1 with a median delta haemoglobin of 1.8 [0.0 to 3.6] g dl-1. Thirty-day morbidity was 47.8% with an overall mortality of 11.3%. CONCLUSIONS: Results indicate lower transfusion-triggering haemoglobin thresholds in clinical practice than suggested by current guidelines. The high morbidity and mortality of this NECTARINE sub-cohort calls for investigative action and evidence-based guidelines addressing peri-operative red blood cell transfusions strategies. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02350348
Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study
Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world.
Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231.
Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001).
Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication
Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit)
Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21) (q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median diseasefree (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P <0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P <0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk score)
- …